Ambergris

Other Names

Âmbar cinzaAmbergreaseAmbergreeseAmbergrijsAmbraAmbra GrigiaAmbra griseaAmbre grisAnbarDragon's spittle perfumeGrauer AmberGray amberGrey amberKunsurano fuuLóng xián xiāngLung sien hiangSugandhadravyaSugandhakaWhale droppings

Synopsis

Ambergris (Ambra grisea)

1. Identity, Source, and Physical Description

Ambergris is a pathological concretion formed in the intestines of the sperm whale (Physeter macrocephalus). Because it was picked up as drift along the shores of the North Sea, ambergris was likened to the amber of the same region, and its name is derived from the French words for "gray amber." In scientific and pharmacological literature it has been referred to variously as Ambra grisea (its Latin designation), ambre gris, and, in classical Arabic tradition, anbar. In Ayurvedic medicine it is known as Agnijara or Agnijvar, and in traditional Chinese sources as Long Xian Xiang ("Dragon's Spittle Fragrance").

The whale coats indigestible squid beaks in a cholesterol-rich secretion; over time, the mass solidifies. Freshly expelled, it is black, soft, and strongly fecal. After years — sometimes decades — of floating in salt water and UV exposure, oxidation transforms it into pale grey or white ambergris: hard, waxy, and dry, smelling nothing like its origins.

Ambergris is found in lumps of various shapes and sizes, ranging from 15 grams up to 420 kilograms. Scientists estimate that ambergris is found in the intestine of only 1–5% of sperm whales or pygmy sperm whales. Ambergris is found primarily in the Atlantic Ocean and on the coasts of South Africa; Brazil; Madagascar; the East Indies; The Maldives; China; Japan; India; Australia; New Zealand; and the Molucca Islands.

Common Forms and Preparations

Raw chunk or lump: Natural, unprocessed beachcast material, graded by color (white/grey, gold/brown, black).
Alcoholic tincture: The key component ambrein can be isolated by dissolving ambergris in hot ethanol and filtering off the white crystals. Tinctures prepared in spirits of wine have been used historically in perfumery and pharmacy.
Attar/perfume oil: Ambergris dissolved or macerated in fixed oils for use in traditional medicine and fragrance.
Culinary use: It has been used as a flavoring agent in Turkish coffee and in hot chocolate in 18th-century Europe.
Traditional medicinal preparations: In the Middle East and South Asia, ambergris was regularly combined with other herbs and spices to create potent medicinal elixirs. When used in herbal combinations, ambergris was often blended with ingredients such as saffron, musk, cinnamon, and sandalwood.
Incense: One of the earliest known uses was in ancient Egypt, where it was burned as incense. The Egyptians believed that the sweet, earthy scent of ambergris could purify the air and ward off evil spirits.

2. Traditional and Historical Use

Ancient Egypt and the Middle East

Ambergris has been used for more than just perfume. Early Arab civilisations named it anbar and used it as incense, an aphrodisiac, and medicine to cure many ailments, including those of the brain, heart, and senses. Mixed with wine, it was considered an aphrodisiac, used to ward off the plague, and as a medicine to treat headaches, colds, epilepsy, and other illnesses.

Arab and Islamic Scholarly Tradition

The first evidence of the use of ambergris in fine perfumery comes from the Arabs in Spain in the 10th century. For this purpose, ambergris was already imported from the Sunda Islands and the Maghreb. At the beginning of the modern era, ambergris was traded throughout Europe and in many cases was weighed out with gold. Al-Hasan ibn Mohammed al-Wassan wrote that the price of one pound of ambergris on the market in Fez was 60 ducats, which corresponded to that of three slaves. The famous Muslim scholar and traveler Ibn Battuta also wrote about ambergris and its exclusive value in pre-modern history.

China

The ancient Chinese called the substance "Dragon's Spittle Fragrance" or Long Xian Xiang. It is highly valued for both its fragrance and its medical value. Textbooks such as the Chinese Bencao Gangmu (Compendium of Materia Medica) recorded ambergris as having healing properties, including aiding blood circulation, invigorating the kidneys, and relieving pain. It was used in traditional medicine to treat respiratory ailments, abdominal pain, and urinary blockages.

India: Ayurveda and Unani Medicine

In India, ambergris is used in perfumes and drugs in Ayurveda and Unani systems of medicine. There is no mention of this product in any of the Ayurvedic classical books like Charaka Samhita or Sushruta Samhita. The Rasa Shastra book Rasarnava mentioned Agnijara for the first time. The product has been classified under "Sadharana Rasa" according to various Rasashastra texts. Used for centuries in Unani and Ayurveda systems of medicine, ambergris has a traditional role as an aphrodisiac and is used in formulas that treat sexual debility, premature ejaculation, and in tonic formulas for the heart, liver, brain, and kidneys. This substance has been widely used in Indian traditional medicine (Ayurveda) and the Unani system of medicine for treating weakness, fever, typhoid, epilepsy, hysteria, and many other nervous disorders and mental-emotional afflictions by combining with other medicinal herbs. The traditional Ayurvedic dosage is described as 120–360 mg mixed with ghee, butter, or honey.

Medieval and Early Modern Europe

In Europe, during the Middle Ages, ambergris has been used as a medicine for treating colds, headaches, and epilepsy. Ambergris was not only a medicinal substance but also a luxury item associated with elite social status, prominently featured in the perfumed lifestyles of figures like Catherine de' Medici and Charles I. By the 17th century, European apothecaries prescribed ambergris for ailments ranging from headaches to epilepsy.

Japan

The Japanese make copious use of ambergris in their highly refined art of Kodo and the diversified cultural practice of incense making, particularly in high-end agarwood-based Senkoh.

3. Key Constituents and Active Compounds

Primary Constituents

In 1946, chemists Leopold Ružička (a 1939 Nobel laureate) and F. Lardon at ETH Zurich reported that ambergris has three main components: the triterpene alcohol ambrein, the steroid alcohol epicoprostanol, and the steroid ketone coprostanone. More detailed analyses have refined this picture: ambergris is known to contain ambrein (25–45%), epicoprostanol (30–40%), coprosterol (1–5%), cholesterol (0–1%), coprostan-3-one (3–4%), and some esterified and free acids and alkaloids.

Ambrein

Ambrein (C₃₀H₅₂O) was first isolated from ambergris in 1820. Its chemical structure is a tricyclic triterpene alcohol containing one tertiary hydroxyl group and two double bonds. Pure ambrein can be obtained through repeated crystallization from alcoholic extracts of raw ambergris, yielding colorless crystals with a melting point of 82–83 °C. Although ambrein itself is odorless, it serves as the biological precursor for aromatic derivatives such as ambroxide and is thought to possess fixative properties for other odorants.

Odiferous Degradation Products

Ambrein itself is nearly odorless. Through photo-oxidation, it degrades into ambroxide (CAS 6790-58-5, C₁₆H₂₈O) — the compound responsible for the characteristic amber-marine scent. To reach its full olfactory potential, ambergris needs to float through the ocean, degrading and photo-oxidizing into a suite of compounds. While at sea, ambrein can split into a shorter monocyclic compound called gamma-dihydroionone that smells of tobacco. Adding a methylene group results in a compound that smells of seawater. A mouldy aroma comes from the addition of a second carbon ring to form alpha-ambrinol. Most important in the cocktail is a tricyclic compound known as ambergris-oxide or naphthofuran, the final breakdown product of ambrein, which smells like ambergris itself.

Biosynthetic Origin

Ambrein is synthesized from the common triterpenoid precursor squalene. The squalene-hopene cyclase (SHC) catalyzes the cyclization of squalene into the monocyclic 3-deoxyachilleol A. Modern biotechnology has produced ambrein biosynthetically: the ambrein biosynthesis pathway has been successfully constructed in model microorganisms, leading to de novo biosynthesis of ambrein from glucose and glycerol.

4. Mechanisms of Action (Preclinical Evidence)

Analgesic / Antinociceptive Mechanism

Studies have demonstrated anti-inflammatory and antinociceptive properties of ambrein and gave clues as to the possible interaction between ambrein and prostaglandins in mediation of pain. The opioid receptors appear to be involved in ambrein antinociception with possible roles for serotonergic and noradrenergic systems. The anti-inflammatory activity of ambrein is probably due to inhibition of systemically released serotonin and/or prostaglandins.

Smooth Muscle / Spasmolytic Mechanism

Ambrein has been shown to decrease spontaneous contractions of smooth muscles in rats, guinea pigs, and rabbits. It reduces these contractions by serving as an antagonist and interfering with Ca²⁺ ions from outside the cell. More precisely, ambrein-induced non-selective dose-dependent antagonism to the effects of some agonists (acetylcholine, adrenaline, noradrenaline, prostaglandins, and oxytocin) in some smooth muscles may be due to the ability of this compound to interfere with the mobilisation of extracellular Ca²⁺ required for muscular contractions induced by these agonists.

Aphrodisiac / Hormonal Mechanism

For increasing libido, ambrein, a major constituent of Ambra grisea, is used in Arab countries. This tricyclic triterpene alcohol increases the concentration of several anterior pituitary hormones and serum testosterone. Additionally, ambrein elevates testosterone concentrations, further supporting its pro-sexual effects in preclinical settings.

Hypoglycemic Mechanism

Ambrein did not reduce the hyperglycemia of glucose-loaded rats given mannoheptulose but it reduced the hyperglycemia of glucose-loaded rats in the absence of mannoheptulose. Results suggested that the hypoglycemic activity of ambrein may be mediated by enhanced glucose utilization.

Anti-inflammatory / Neutrophil Inhibition

Ambrein also inhibits human neutrophil function, contributing to anti-inflammatory modulation. The cytotoxic activities of ambrein and its derivatives were investigated against human liver carcinoma (Hepa59T/VGH), colon adenocarcinoma (WiDr), lung carcinoma (A-549), and human breast adenocarcinoma (MCF-7) cell lines. The anti-inflammatory activities, in terms of the inhibition of human neutrophil function, were also evaluated.

5. Scientific Evidence by Area of Use

Important general caveat: No human clinical trials have been conducted to date on ambrein or ambergris as medicinal interventions. All mechanistic and pharmacological studies discussed below are animal or in vitro studies, and the evidence base must be characterized as preliminary and preclinical. Further studies and clinical trials should be conducted to support its therapeutic uses.

5.1 Pain (Antinociception)

The compound ambrein was isolated from ambergris, which is commonly used as an analgesic in Saudi folklore medicine. The key preclinical study, published in the Japanese Journal of Pharmacology (Taha, 1992), was a rodent hot-plate and writhing-test investigation: in the hot-plate test, ambrein was found to possess antinociceptive activity in mice at doses which did not sedate or incapacitate the animals. By the intraperitoneal (i.p.) administration route, ambrein produced antinociception in mice at a dose as low as 10 mg/kg. The antinociceptive activity of ambrein (250 mg/kg i.p.) was inhibited by a noradrenergic neurotoxin (DSP-4) and by naloxone, methysergide, or prazosin. It was not influenced by a serotonin depletor, p-chlorophenylalanine. Evidence strength: Animal model only; no human evidence.

5.2 Aphrodisiac / Sexual Function

A published rodent study (Taha et al., 1995, Archives Internationales de Pharmacodynamie et de Thérapie) examined copulatory behavior: the effect of ambrein was studied on the sexual behavior of male rats. The rats were administered ambrein in doses of 100 and 300 mg/kg body weight. Male sexual activities were assessed by recording erectile responses and mountings in the absence of females. Copulatory studies were carried out by caging males with receptive females brought into estrus with subcutaneous injections of estradiol benzoate and progesterone. The copulatory pattern (mountings, intromissions, ejaculations, and refractory period), pendiculations, and orientation activities were recorded. Ambrein produced recurrent episodes of penile erection, a dose-dependent, vigorous and repetitive increase in intromissions, and increased anogenital investigatory behavior, identifying the drug as a sexual stimulant. It is conceivable that the ambrein-modified masculine sexual behavior in male rats supports the folk use of this drug as an aphrodisiac. In a separate study, effects of ambergris on sexual desire and body weights owing to its influence on endocrine hormones were shown. There was a substantial rise in testosterone, estradiol, prolactin, insulin, cortisol, thyroxin (T4) levels, and body weights after ambergris administration. Evidence strength: Animal studies only; no controlled human trials.

5.3 Smooth Muscle Relaxation / Spasmolytic Activity

A Journal of Ethnopharmacology-published tissue-bath study (Taha et al., 1998) investigated ambrein on isolated smooth muscle preparations: the pharmacological effects of ambrein on the contractile responses induced by some agonists in smooth muscle preparations were investigated. Ambrein in the concentration range of 10, 50, and 250 μg/ml decreased the spontaneous contraction of the isolated rabbit jejunum, rat uterus, and guinea-pig vas deferens. Ambrein-induced antagonism to acetylcholine in the guinea-pig ileum was abolished when the concentration of calcium chloride in the Tyrode's solution was increased to 5 mM/l. Furthermore, ambrein did not antagonise nicotine-induced contractions in the isolated rabbit jejunum or serotonin-induced contractions in isolated guinea-pig ileum and vas deferens or the rat uterus. However, ambrein in the concentration range of 10, 50, and 250 μg/ml antagonised prostaglandins E₂, D₂, F₂α, and oxytocin-induced contractions in the rat uterus in vitro. Evidence strength: In vitro isolated tissue only; no in vivo or human data.

5.4 Blood Glucose / Hypoglycemic Activity

A rodent study (Taha, 1991, Journal of Ethnopharmacology, PMID 1809819) examined ambrein's effects on blood glucose: ambrein reduced the blood glucose level of normal and moderately alloxan-diabetic rats but did not reduce the blood glucose levels of severely-diabetic rats. Ambrein did not reduce the hyperglycemia of glucose-loaded rats given mannoheptulose but it reduced the hyperglycemia of glucose-loaded rats in the absence of mannoheptulose. Results suggested that the hypoglycemic activity of ambrein may be mediated by enhanced glucose utilization. Evidence strength: Rodent model only; no human evidence.

5.5 Antioxidant Activity

A study published in Food and Chemical Toxicology (Raza et al., 2007, PMID 17408835) evaluated ambrein and epicoprostanol for antioxidant potential: ambrein and epicoprostanol were evaluated for antioxidant potential in vitro by chemiluminescence, as well as in vivo using lipid peroxides and glutathione levels as indicators in liver tissue of rats treated with adriamycin (doxorubicin), a well-known free-radical-producing drug. In the in vitro test, the inhibition in chemiluminescence by ambrein was dose-dependent. Both high concentrations of ambrein (20–40 μg/ml) inhibited the chemiluminescence response significantly (P<0.05 and P<0.01, respectively) when compared to control. Ambrein (25 and 50 mg/kg) treatment as a solo therapy at both dose levels significantly (P<0.001) decreased malondialdehyde (MDA) contents in liver tissue. From the results of these experiments, it seems that ambrein at all concentrations behaves like an antioxidant in in vitro studies, but at the same time it decreased NP-SH contents in vivo accompanied by a decline in MDA contents. Evidence strength: Preclinical (in vitro and rodent); no human evidence.

5.6 Cytotoxic / Anticancer Activity

A study published in the Journal of Natural Products (Shen et al., 2007, PMID 17315955) prepared ten new derivatives of ambrein and assessed biological activity: the cytotoxic activities of ambrein and derivatives (1–12) were investigated against human liver carcinoma (Hepa59T/VGH), colon adenocarcinoma (WiDr), lung carcinoma (A-549), and human breast adenocarcinoma (MCF-7) cell lines. Anti-inflammatory activities, in terms of the inhibition of human neutrophil function, were also evaluated. These were in vitro cell-line experiments. Evidence strength: In vitro only; no animal or human evidence for anticancer efficacy.

5.7 Biochemical and Hematological Safety Profile (Preclinical)

A safety-oriented rodent study (PMID 7630038) examined plasma biochemistry: biochemical effects of acute and subacute treatments with ambrein were investigated in rats by measuring total proteins, cholesterol, triglycerides, GOT, GPT, and alkaline phosphatase in blood plasma. Determinations of prothrombin time (PT), partial thrombin time (PTT), thrombin time (TT), and fibrinogen level were also performed. Ambrein administered i.p. did not cause any toxic symptoms in the liver as revealed by histology of liver tissue in both acute and subacute treatments. Ambrein itself did not significantly affect the plasma protein, cholesterol, GOT, and GPT profiles, but lowered alkaline phosphatase at high doses (50 and 250 mg/kg) after subacute treatment. However, it increased PT, PTT, and TT and decreased fibrinogen levels in both the acute and subacute studies, suggesting a possible anticoagulant-like effect that warrants attention.

6. Body Systems and Health Areas of Association

Nervous system / Pain: Traditional use in analgesia and epilepsy; preclinical antinociceptive activity demonstrated through opioid, serotonergic, and noradrenergic pathways.
Reproductive / Endocrine system: Extensive traditional use as an aphrodisiac across Arab, South Asian, and European cultures; preclinical evidence of increased testosterone and anterior pituitary hormones, and pro-copulatory behavior in male rats.
Smooth muscle / Gastrointestinal and uterine systems: In vitro spasmolytic activity; literature shows ambergris was used in traditional medicine to cure migraine headaches, common colds, and constipation.
Metabolic / Glycemic control: Preclinical hypoglycemic effect via enhanced glucose utilization in rodent models.
Cardiovascular system: Animal studies have demonstrated possible effects on the cardiovascular system. The preclinical anticoagulant signal (altered PT, PTT, TT) also touches cardiovascular and hematological domains.
Immune and inflammatory systems: Preclinical inhibition of human neutrophil function and interaction with prostaglandin-mediated pathways.
Oxidative stress: Dose-dependent in vitro antioxidant effects and attenuation of adriamycin-induced lipid peroxidation in rodent liver.
Oncology (exploratory): In vitro cytotoxic effects against multiple carcinoma cell lines from ambrein derivatives.
Mental and emotional well-being: In Eastern cultures, ambergris is used for medicines and potions and as a spice. Traditional Unani and Ayurvedic texts describe its use for hysteria, nervous disorders, and strengthening brain function, although no modern clinical evidence supports these indications.

7. Dosage Forms and Reported Dosages

Because no human clinical trials have been conducted, all dosage information is either from traditional/ethnopharmacological records or from animal pharmacology studies. These figures are reported strictly as stated in the cited sources and should not be interpreted as recommendations.

Ayurvedic traditional dose: 120–360 mg mixed with ghee, butter, or honey.
Analgesic study in mice (Taha, 1992, PMID 1479744): By the i.p. administration route, ambrein produced antinociception in mice at a dose as low as 10 mg/kg. Higher doses up to 250 mg/kg i.p. were also tested for mechanistic studies.
Aphrodisiac study in rats (Taha et al., 1995, PMID 8540767): The effect of ambrein was studied on the sexual behavior of male rats. The rats were administered ambrein in doses of 100 and 300 mg/kg body weight.
Smooth muscle study (Taha et al., 1998, PMID 9533428): Ambrein in the concentration range of 10, 50, and 250 μg/ml decreased the spontaneous contraction of the isolated rabbit jejunum, rat uterus, and guinea-pig vas deferens.
Antioxidant study in rats (Raza et al., 2007, PMID 17408835): Ambrein (25 and 50 mg/kg) treatment as a solo therapy at both dose levels significantly (P<0.001) decreased MDA contents in liver tissue.
Acute toxicity in mice (Taha, 1992): The LD₅₀ of ambrein, given intraperitoneally in mice, was found to be high (7.5 g/kg), and ambrein proved to be a safe compound in this species.

8. Safety Considerations

Preclinical Toxicological Findings

Ambrein administered intraperitoneally did not cause any toxic symptoms in the liver as revealed by histology of liver tissue in both acute and subacute treatments. Ambrein itself did not significantly affect the plasma protein, cholesterol, GOT, and GPT profiles, but lowered alkaline phosphatase at high doses (50 and 250 mg/kg) after subacute treatment. However, it increased prothrombin time (PT), partial thrombin time (PTT), thrombin time (TT), and decreased fibrinogen levels in both the acute and subacute studies. This preclinical signal indicates a potential anticoagulant-like interaction with coagulation pathways, a finding of possible clinical relevance that has not been evaluated in humans.

Absence of Human Safety Data

The biological activities of natural ambrein, the main component of ambergris, have not been assessed extensively due to its scarcity. No controlled human studies on safety, tolerability, drug interactions, or adverse effects have been published. The preclinical coagulation findings raise theoretical concerns about use alongside anticoagulant or antiplatelet medications, but this has not been investigated in humans.

Legal and Regulatory Considerations

Ambergris is treated differently from other whale products, since CITES (the Convention on International Trade in Endangered Species) regards the substance as an excretion and therefore as a benign byproduct, hence not requiring coverage under the Convention. The EU is currently happy to support this definition. However, national laws diverge substantially:

United States: Ambergris is created when secretions form around squid beaks and cuttlefish parts in the intestinal tract of a whale. You may not collect, keep, or sell ambergris because it is a part from an endangered marine mammal. In the United States, ambergris falls under the Marine Mammal Protection Act and the Endangered Species Act because it comes from sperm whales, which are protected.
Australia: In Australia, ambergris is considered to be a whale product and therefore its export and import is regulated under part 13A of the Environment Protection and Biodiversity Conservation Act, 1999. Commercial export permits for ambergris will not be granted and there are substantial penalties for attempting to export ambergris without the proper CITES documentation.
India: India bans ambergris under the Wildlife Protection Act of 1972 (amended in 2022). Sperm whales receive the highest level of protection under Schedule 1 of the Act, and possession of ambergris is treated as possession of a protected wildlife product.
UK and EU: In the UK and most of the EU, it is legal to collect and sell beachcast ambergris, since CITES classifies it as an excretion rather than a body part.
New Zealand: Collecting naturally separated ambergris requires no permit, but finders must report it to the Department of Conservation as soon as practicable under the Marine Mammals Protection Act 1978. That reporting creates a paper trail, which becomes important if the finder later wants to export the ambergris.

Synthetic Alternatives

Due to legal constraints and scarcity, the fragrance industry now relies primarily on synthetic equivalents. Ambrein has only a mild scent, but it can be oxidized to produce the odor components ambroxide and ambrinol. Ambroxide (trade name Ambroxan) is widely used in the perfume industry; but because ambrein is now scarce, the industry relies on synthetic ambroxide. Commercial synthesis routes from sclareol — a diterpene extracted from clary sage (Salvia sclarea) — have been available since the 1950s. The dominant industrial pathway runs four steps: sclareol is oxidatively cleaved to sclareolide, reduced to ambradiol, then cyclodehydrated to yield ambroxide.

9. Summary of Evidence Strength

Ambergris and its primary active constituent ambrein have a rich cross-cultural history of medicinal use spanning more than a millennium. However, the scientific evidence base for any therapeutic claim remains entirely preclinical. To date, only aphrodisiac, antinociceptive, and elastase release inhibitory activities are known from formal pharmacological investigation, and all of these findings derive from rodent or isolated tissue experiments. There are further studies and clinical trials that should be conducted to support its therapeutic uses. No systematic reviews, meta-analyses, or human clinical trials exist. The pharmacological profile of ambrein — encompassing antinociceptive, spasmolytic, aphrodisiac, hypoglycemic, antioxidant, and putative anticoagulant activities — is intriguing from a natural products perspective, but translational evidence in humans is entirely absent. The extreme rarity and legal restrictions surrounding natural ambergris have significantly hampered research, a situation that ongoing biosynthetic production methods may begin to address.

References

Health Conditions

Health conditions that Ambergris may help support.

No conditions available.

Body Systems

Body systems that Ambergris may help support.

No body systems available.